Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjects

European Cytokine Network

Volumn 18, Issue 2, 2007, Pages 49-58

  Pott, Gregory B ^a,b   Sailer, Carrie A ^a,b   Porat, Reuven ^c   Peskind, Robert L ^d,j   Fuchs, Amy C ^c   Angel, Jonathan B ^e   Skolnik, Paul R ^f   Jacobson, Mark A ^g   Giordano, Michael F ^h,k   LeBeaut, Alexandre ^i,l   Grint, Paul C ^i,m   Dinarello, Charles A ^a   Shapiro, Leland ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Dept Medicine   (Israel)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF OTTAWA   (Canada)

^f BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j Poudre Valley Hospital   (United States)

^k BRISTOL MYERS SQUIBB   (United States)

^l NOVARTIS PHARMA AG   (Switzerland)

^m Kalypsys Inc   (United States)

more..

Author keywords

Ex vivo; HIV 1; Interleukin 10; Pro inflammatory cytokines; Whole blood

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 18; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PLACEBO; PROTEIN P55; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ARTICLE; BLOOD CULTURE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; PLACEBOS; PROSPECTIVE STUDIES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34547907120     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2007.0094     Document Type: Article

References (38)

1. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17.
2. Young B, Johnson S, Bahktiari M, Shugarts D, Young RK, Allen M. Ramey RRn, Kuritzkes DR. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis 1998; 178: 1497.
3. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron Jr. JJ, Feinberg JE, Balfour Jr. HH, Deyton LR, Chodakewitz JA, Fischl MA. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725.
4. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, Richman DD. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA Panel. JAMA 1998; 279: 1984.
5. Hammer SM, Gillis JM, Groopman JE, Rose RM. In vitro modification of human immunodeficiency virus infection by granulocytemacrophage colony-stimulating factor and gamma interferon. Proc Natl Acad Sci USA 1986; 83: 8734.
6. Kornbluth RS, Oh PS, Munis JR, Cleveland PH, Richman DD. Interferons and bacterial lipopolysaccharide protect macrophages from productive infection by human immunodeficiency virus in vitro. J Exp Med 1989; 169: 1137.
7. Granowitz EV, Saget BM, Wang MZ, Dinarello CA, Skolnik PR. Interleukin 1 induces HIV-1 expression in chronically infected U1 cells: blockade by interleukin 1 receptor antagonist and tumor necrosis factor binding protein type 1. Mol Med 1995; 1: 667.
8. Poli G, Kinter AL, Fauci AS. Interleukin 1 induces expression of the human immunodeficiency virus alone and in synergy with interleukin 6 in chronically infected U1 cells: inhibition of inductive effects by the interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1994; 91: 108.
9. Choi HJ, Dinarello CA, Shapiro L. Interleukin-18 inhibits human immunodeficiency virus type 1 production in peripheral blood mononuclear cells. J Infect Dis 2001; 184: 560.
10. Oravecz T, Pall M, Norcross MA. Beta-chemokine inhibition of monocytotropic HIV-1 infection. Interference with a postbinding fusion step. J lmmunol 1996; 157: 1329.
11. Howard M, O'Garra A. Biological properties of interleukin 10. Immunol Today 1992; 13: 198.
12. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815.
13. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10- deficient mice develop chronic enterocolitis. Cell 1993; 75: 263.
14. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, Thompson-Snipes L, Leach MW, Rennick D. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996; 98: 1010.
15. Mellors JW, Griffith BP, Ortiz MA, Landry ML, Ryan JL. Tumor necrosis factor-alpha/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages. J Infect Dis 1991; 163: 78.
16. Poli G, Kinter AL, Vicenzi E, Fauci AS. Cytokine regulation of acute and chronic HIV infection in vitro: from cell lines to primary mononuclear cells. Res Immunol 1994; 145: 578.
17. Rizzardi GP, Barcellini W, Tambussi G, Lillo F, Malnati M, Perrin L, Lazzarin A. Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. AIDS 1996; 10: F45.
18. Scott-Algara D, Vuillier F, Marasescu M, de Saint Martin J, Dighiero G. Serum levels of IL-2, IL-1 alpha, TNF-alpha, and soluble receptor of IL-2 in HIV-1-infected patients. AIDS Res Hum Retroviruses 1991; 7: 381.
19. von Sydow M, Sonnerborg A, Gaines H, Strannegard O. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. AIDS Res Hum Retroviruses 1991; 7: 375.
20. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444.
21. Weissman D, Ostrowski M, Daucher JA, Gantt K, Blauvelt A, Altman D, Shen L, Ehler L, Hoxie J, Grint P, Katz SI, Fauci AS. Interleukin-10 Decreases HIV Plasma Viral Load: Results of a Phase I Clinical Trial. 4th Conference on Retroviruses and Opportunistic Infections 1997.
22. Montaner LJ, Griffin P, Gordon S. Interleukin-10 inhibits initial reverse transcription of human immunodeficiency virus type 1 and mediates a virostatic latent state in primary blood-derived human macrophages in vitro. J Gen Virol 1994; 75(Pt 12): 3393.
23. Naif HM, Chang J, Ho-Shon M, Li S, Cunningham AL. Inhibition of human immunodeficiency virus replication in differentiating monocytes by interleukin 10 occurs in parallel with inhibition of cellular RNA expression. AIDS Res Hum Retroviruses 1996; 12: 1237.
24. Saville MW, Taga K, Foli A, Broder S, Tosato G, Yarchoan R. Interleukin-10 suppresses human immunodeficiency virus-1 replication in vitro in cells of the monocyte/macrophage lineage. Blood 1994; 83: 3591.
25. Angel JB, Jacobson MA, Skolnik PR, Giordano M, Shapiro L, LeBeaut A, Greaves W, Fuchs AC. A multicenter, randomized, double-blind, placebo-controlled trial of recombinant human interleukin-10 in HIV-infected subjects. AIDS 2000; 14: 2503.
26. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 154: 5492.
27. Muhl H, Dinarello CA. Macrophage inflammatory protein-1 alpha production in lipopolysaccharide-stimulated human adherent blood mononuclear cells is inhibited by the nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine. J lmmunol 1997; 159: 5063.
28. Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD 14+ human blood mononuclear cells. J Clin Invest 1998; 101: 711.
29. Shapiro L, Clark BD, Orencole SF, Poutsiaka DD, Granowitz EV, Dinarello CA. Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J Infect Dis 1993; 167: 1344.
30. Ito M, Baba M, Sato A, Hirabayashi K, Tanabe F, Shigeta S, De Clercq E. Tumor necrosis factor enhances replication of human immunodeficiency virus (HIV) in vitro. Biochem Biophys Res Commun 1989; 158: 307.
31. Weissman D, Poli G, Fauci AS. Interleukin 10 blocks HIV replication in macrophages by inhibiting the autocrine loop of tumor necrosis factor alpha and interleukin 6 induction of virus. AIDS Res Hum Retroviruses 1994; 10: 1199.
32. Angel JB, Saget BM, Wang MZ, Wang A, Dinarello CA, Skolnik PR. Interleukin-10 enhances human immunodeficiency virus type 1 expression in a chronically infected promonocytic cell line (U1) by a tumor necrosis factor alpha-independent mechanism. J Interferon Cytokine Res 1995; 15: 575.
33. Barcellini W, Rizzardi GP, Marriott JB, Fain C, Shattock RJ, Meroni PL, Poli G, Dalgleish AG. Interleukin-10-induced HIV-1 expression is mediated by induction of both membrane-bound tumour necrosis factor (TNF)-alpha and TNF receptor type 1 in a promonocytic cell line. AIDS 1996; 10: 835.
34. Finnegan A, Roebuck KA, Nakai BE, Gu DS, Rabbi MF, Song S, Landay AL. IL-10 cooperates with TNF-alpha to activate HIV-1 from latently and acutely infected cells of monocyte/macrophage lineage. J Immunol 1996; 156: 841.
35. Weissman D, Poli G, Fauci AS. IL-10 synergizes with multiple cytokines in enhancing HIV production in cells of monocytic lineage. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 442.
36. Puren AJ, Razeghi P, Fantuzzi G, Dinarello CA. Interleukin-18 enhances lipopolysaccharide-induced interferon-gamma production in human whole blood cultures. J Infect Dis 1998; 178: 1830.
37. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209.
38. Fuchs AC, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Radwanski E, Affrime MB, Cutler DL, Grint PC, Dinarello CA. Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J Clin Immunol 1996; 16: 291.